Enter multiple symbols separated by commas

Stocks Teva Pharmaceutical Industries Ltd


  • TEL AVIV, Oct 1- Teva Pharmaceutical Industries has struck a deal to buy Mexican drugmaker Representaciones e Investigaciones Médicas SA for $2.3 billion to strengthen its presence in Latin America. It is Teva's second major acquisition in recent months; in late July it agreed to pay $40.5 billion in cash and stock for Allergan's generics drug business to...

  • Sept 24- GlaxoSmithKline Plc said the European health regulator had recommended an approval for its injectable drug to treat asthma patients who don't respond well to traditional inhalers. GSK and other drugmakers including AstraZeneca Plc, Roche Holding AG, Teva Pharmaceutical Industries Ltd and Sanofi SA are developing drugs that take a more...

  • Allergan CEO fires back on Hillary Clinton tweet Monday, 21 Sep 2015 | 6:24 PM ET
    Brent Saunders, CEO of Allergan.

    Jim Cramer speaks to the CEO of Allergan on the impact of Hillary Clinton's tweet about drug pricing and her impact on the industry.

  • Sept 17- A U.S. appeals court has ruled that President Barack Obama's healthcare law violates the rights of religiously affiliated employers by forcing them to help provide contraceptive coverage even though they do not have to pay for it. Parting ways with all other appeals courts that have considered the issue, the 8th U.S. Circuit Court of Appeals in St. Louis...

  • NEW YORK, Aug 6- Generic drugmaker Mylan Inc's chief executive said on Thursday that acquiring Perrigo Co was not a must and that it has other options should Perrigo successfully fend off Mylan's $34 billion hostile offer. However, Mylan CEO Heather Bresch said in an interview that getting the Perrigo deal done remains a top priority and that she still believes...

  • UPDATE 2-Allergan reports better-than-expected revenue Thursday, 6 Aug 2015 | 9:33 AM ET

    Aug 6- Irish drugmaker Allergan Plc reported better-than-expected revenue for the first full quarter since the merger of Actavis and Allergan. Allergan, which changed its name from Actavis after the deal closed, said adding signature drugs like Botox and eye drops Restasis boosted branded products sales five-fold to $3.71 billion in the second quarter...

  • Aug 6- Drugmaker Mylan Inc reported a better-than-expected quarterly profit as it sold more generic drugs in North America, and said it remained committed to its acquisition of Perrigo Co Plc. Mylan, which also raised its full-year earnings forecast, has been pursuing Perrigo since April in an attempt to boost its over-the-counter drug business and extend its...

  • Aug 6- Botox-maker Allergan Plc posted a better-than-expected quarterly adjusted profit as sales of branded drugs rose, helped by acquisition of new products. Allergan did not provide an update to its sales forecast for the full year. Dublin, Ireland- based Allergan's net revenue for the quarter more than doubled to $5.76 billion.

  • Teva's MS drug Copaxone has strong second-quarter sales Thursday, 30 Jul 2015 | 8:42 AM ET

    JERUSALEM, July 30- Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world's biggest generic drug maker, said that global...

  • Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower under pressure from an overnight plunge in the Shanghai Composite and a continued decline in commodities.

  • Europe stocks close 2% down after China rout Monday, 27 Jul 2015 | 11:30 AM ET
    An employee talks on the phone as he views trading screens at the offices of Panmure Gordon and Co.

    European stock closed lower on Monday, after a sharp selloff in Asian shares highlighted concerns about Chinese market volatility and slowing growth.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • Early movers: AGN, MYL, MHFI, UBS, FCAU & more Monday, 27 Jul 2015 | 7:48 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • Teva to buy Allergan's generics business for $40.5B Monday, 27 Jul 2015 | 7:38 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and...

  • Allergan buys Naurex for $560M as deal talk swirls Sunday, 26 Jul 2015 | 11:20 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.

  • Teva closes in on Allergan’s generics unit Sunday, 26 Jul 2015 | 5:45 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva Pharmaceutical is nearing a deal to acquire Allergan's generics drug unit for between $40bn and $45bn, according to people familiar with the matter. The FT reports.